Close Menu

NEW YORK (GenomeWeb) – Lucence Diagnostics and Singapore's Quest Laboratories have announced a new partnership under which Quest will offer blood tests developed by Lucence for cancer detection and treatment guidance to its customers in the region.

The blood tests will be based on Lucence's proprietary liquid biopsy technology. The company says it has developed assays for cancers common in Asia, like lung and colon cancer. The same tests can also read out germline cancer predisposition mutations like BRCA1 and BRCA2.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Apr
16
Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.